SEC Form 4 · accession 0001214659-18-000295
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Craig Thompson
Officer — President & CEO · Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 6:37 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.65 | Jan 5, 2018 | A | 1,847,074 | A | — | Jan 5, 2028 | Common Stock | 1,847,074 | 1,847,074 | D |
Explanation of responses
- F125% of this option is vested immediately on grant date and 75% of this option vests monthly over 36 months from the vesting commencement date of January 5, 2018.